Biopharmaceutical News and Research

RSS

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.

11 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Pharmaceutical scientists at the University of Sunderland have been awarded £125,000 by the Cystinosis Foundation (CF) UK to fund the next stage of their research into a rare genetic disease.

7 Mar 2013

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags.

6 Mar 2013

Cliantha Research chooses Acceliant's eClinical Suite for clinical trial data management needs

Acceliant, a global technology provider of innovative clinical trial data management solutions, today announced that Cliantha Research, a leading global Contract Research Organization, has chosen Acceliant's eClinical Suite for their clinical trial data management needs.

27 Feb 2013

Smoking prevention and cessation campaigns: an interview with Dr DePinho, University of Texas MD Anderson Cancer Center and Dr Mohar, National Cancer Institute of Mexico

There are more than 94 million former and current smokers in the United States, and more than 21 million in Mexico, according to the 2009 Global Adult Tobacco Survey (GATS) Fact Sheet.

27 Feb 2013

Sius single-use tangential flow filtration skid from Novasep

Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the launch of its Sius single-use tangential flow filtration (TFF) skid.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.

19 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

14 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Decade Sunshine, 3SBio enter Merger Agreement

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has entered into an agreement and plan of merger with Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent.

10 Feb 2013

More than £6M funding awarded to enhance development of biopharmaceuticals

More than £6M of funding has been awarded to enhance the development of biopharmaceuticals. In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Biopharmaceutical News and Research

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cliantha Research chooses Acceliant's eClinical Suite for clinical trial data management needs

Smoking prevention and cessation campaigns: an interview with Dr DePinho, University of Texas MD Anderson Cancer Center and Dr Mohar, National Cancer Institute of Mexico

Sius single-use tangential flow filtration skid from Novasep

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Circassia announces results from ToleroMune cat allergy phase II clinical study

Marine-based active substances show promise against multiple myeloma

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Targacept reports net loss of $15.9 million for fourth quarter 2012

Decade Sunshine, 3SBio enter Merger Agreement

More than £6M funding awarded to enhance development of biopharmaceuticals

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News